Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses

Oncolytic viruses (OVs) preferentially infect and kill cancer cells. Additionally, OV-induced immune responses subvert cancer-associated immunosuppression and promote antitumor immunity. We have recently demonstrated that the complementation of oncolytic virotherapy with gemcitabine accentuates its...

Descripción completa

Detalles Bibliográficos
Autores principales: Gujar, Shashi A, Clements, Derek, Lee, Patrick WK
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010537/
https://www.ncbi.nlm.nih.gov/pubmed/24804161
http://dx.doi.org/10.4161/onci.27622
_version_ 1782479875050831872
author Gujar, Shashi A
Clements, Derek
Lee, Patrick WK
author_facet Gujar, Shashi A
Clements, Derek
Lee, Patrick WK
author_sort Gujar, Shashi A
collection PubMed
description Oncolytic viruses (OVs) preferentially infect and kill cancer cells. Additionally, OV-induced immune responses subvert cancer-associated immunosuppression and promote antitumor immunity. We have recently demonstrated that the complementation of oncolytic virotherapy with gemcitabine accentuates its immunostimulatory effects, hence exerting superior antineoplastic activity.
format Online
Article
Text
id pubmed-4010537
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40105372014-05-06 Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses Gujar, Shashi A Clements, Derek Lee, Patrick WK Oncoimmunology Author's View Oncolytic viruses (OVs) preferentially infect and kill cancer cells. Additionally, OV-induced immune responses subvert cancer-associated immunosuppression and promote antitumor immunity. We have recently demonstrated that the complementation of oncolytic virotherapy with gemcitabine accentuates its immunostimulatory effects, hence exerting superior antineoplastic activity. Landes Bioscience 2014-01-06 /pmc/articles/PMC4010537/ /pubmed/24804161 http://dx.doi.org/10.4161/onci.27622 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Gujar, Shashi A
Clements, Derek
Lee, Patrick WK
Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
title Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
title_full Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
title_fullStr Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
title_full_unstemmed Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
title_short Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
title_sort two is better than one: complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010537/
https://www.ncbi.nlm.nih.gov/pubmed/24804161
http://dx.doi.org/10.4161/onci.27622
work_keys_str_mv AT gujarshashia twoisbetterthanonecomplementingoncolyticvirotherapywithgemcitabinetopotentiateantitumorimmuneresponses
AT clementsderek twoisbetterthanonecomplementingoncolyticvirotherapywithgemcitabinetopotentiateantitumorimmuneresponses
AT leepatrickwk twoisbetterthanonecomplementingoncolyticvirotherapywithgemcitabinetopotentiateantitumorimmuneresponses

Ejemplares similares